Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous
paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of
this regimen in previously untreated patients with advanced ovarian carcinoma.